MedBright AI Investments Inc. (Ticker: MBAI.c or MBAIF for US investors), has sparked excitement with today's announcement regarding MedMatrix, a groundbreaking product designed to transform outpatient healthcare facilities.
Today, MBAI revealed that MedMatrix has concluded its beta testing phase with its inaugural clients. Following this testing period, the management has selected a comprehensive suite of five features to offer in the global outpatient facility market.
With this MBAI is trading in the green on above average volume.
For the beta phase MBAI was successfully able to sign up an impressive 14 clinics in just 2 months including a Yale School of Medicine Affiliated Clinic Group
MedMatrix represents a fusion of cutting-edge artificial intelligence and comprehensive data analytics, poised to revolutionize key aspects of healthcare facility management. Through its advanced capabilities, MedMatrix offers a suite of five essential features tailored to optimize patient care, resource allocation, revenue management, and market expansion opportunities.
Trevor Vieweg, CEO of MedBright, expressed his enthusiasm for the completion of the beta phase, emphasizing the revenue-generating potential of MedMatrix's feature set.
Looking ahead, MedMatrix plans to unveil its go-to-market strategy, transitioning beta customers to commercial agreements and expanding its customer base.
Full news here:
https://www.globenewswire.com/news-release/2024/02/27/2835946/0/en/MedMatrix-Product-Moves-from-Beta-to-Full-Commercialization-Announces-AI-Product-Suite.html
Posted on behalf of Medbright AI Investments Inc.